|Articles|April 10, 2009

WOTY- Podcast-Howson

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Image Credit: Adobe Stock Images/Crystal light

FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer

ByDavy James

December 15th 2025

Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results

ByNicholas Jacobus

December 15th 2025

FDA Approves Lerochol for Adults with Elevated LDL Cholesterol

ByNicholas Jacobus

December 15th 2025

Image Credit: Adobe Stock Images/wladimir1804

FDA Grants National Priority Voucher to Tecvayli Combination in Relapsed or Refractory Multiple Myeloma

ByDavy James

December 15th 2025

Sobi Reaches $1.5 Billion Definitive Agreement with Arthrosi Therapeutics to Acquire Gout Treatment

ByNicholas Jacobus

December 15th 2025

WOTY- Podcast-Howson

Newsletter

Related Content

FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer

Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results

FDA Approves Lerochol for Adults with Elevated LDL Cholesterol

FDA Grants National Priority Voucher to Tecvayli Combination in Relapsed or Refractory Multiple Myeloma

Sobi Reaches $1.5 Billion Definitive Agreement with Arthrosi Therapeutics to Acquire Gout Treatment

Trending on PharmExec

Brent Saunders: Eyeing New Horizons

TrumpRX Has a Blind Spot and It Can Redefine Patient Access

FDA Grants National Priority Voucher to Tecvayli Combination in Relapsed or Refractory Multiple Myeloma

Sobi Reaches $1.5 Billion Definitive Agreement with Arthrosi Therapeutics to Acquire Gout Treatment

FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer